BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 20149590)

  • 1. Troponin-I as a prognosticator of mortality in severe sepsis patients.
    John J; Woodward DB; Wang Y; Yan SB; Fisher D; Kinasewitz GT; Heiselman D
    J Crit Care; 2010 Jun; 25(2):270-5. PubMed ID: 20149590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.
    Angus DC; Laterre PF; Helterbrand J; Ely EW; Ball DE; Garg R; Weissfeld LA; Bernard GR;
    Crit Care Med; 2004 Nov; 32(11):2199-206. PubMed ID: 15640631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety.
    Laterre PF; Nelson DR; Macias W; Abraham E; Sashegyi A; Williams MD; Levy M; Levi M; Utterback B; Vincent JL
    J Crit Care; 2007 Jun; 22(2):142-52. PubMed ID: 17548026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.
    Abraham E; Laterre PF; Garg R; Levy H; Talwar D; Trzaskoma BL; François B; Guy JS; Brückmann M; Rea-Neto A; Rossaint R; Perrotin D; Sablotzki A; Arkins N; Utterback BG; Macias WL;
    N Engl J Med; 2005 Sep; 353(13):1332-41. PubMed ID: 16192478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
    Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; McL Booth FV
    Surgery; 2006 Nov; 140(5):726-39. PubMed ID: 17084715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated).
    Shorr AF; Nelson DR; Wyncoll DL; Reinhart K; Brunkhorst F; Vail GM; Janes J
    Crit Care; 2008; 12(2):R45. PubMed ID: 18394162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
    Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; Booth FV
    Surgery; 2007 Apr; 141(4):548-61. PubMed ID: 17431957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activated protein C improves survival in severe sepsis patients with elevated troponin.
    John J; Awab A; Norman D; Dernaika T; Kinasewitz GT
    Intensive Care Med; 2007 Dec; 33(12):2122-8. PubMed ID: 17684722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial.
    Laterre PF; Levy H; Clermont G; Ball DE; Garg R; Nelson DR; Dhainaut JF; Angus DC
    Crit Care Med; 2004 Nov; 32(11):2207-18. PubMed ID: 15640632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis.
    Barie PS; Hydo LJ; Shou J; Eachempati SR
    Surg Infect (Larchmt); 2006; 7 Suppl 2():S77-80. PubMed ID: 16895513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: comparison with a controlled clinical trial.
    Wheeler A; Steingrub J; Schmidt GA; Sanchez P; Jacobi J; Linde-Zwirble W; Bates B; Qualy RL; Woodward B; Zeckel M
    Crit Care Med; 2008 Jan; 36(1):14-23. PubMed ID: 18158435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes.
    Martin G; Brunkhorst FM; Janes JM; Reinhart K; Sundin DP; Garnett K; Beale R
    Crit Care; 2009; 13(3):R103. PubMed ID: 19566927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.
    Nadel S; Goldstein B; Williams MD; Dalton H; Peters M; Macias WL; Abd-Allah SA; Levy H; Angle R; Wang D; Sundin DP; Giroir B;
    Lancet; 2007 Mar; 369(9564):836-843. PubMed ID: 17350452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of cardiac troponin I as a prognosticator in critically ill medical patients: a prospective observational cohort study.
    King DA; Codish S; Novack V; Barski L; Almog Y
    Crit Care; 2005 Aug; 9(4):R390-5. PubMed ID: 16137352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of fluid resuscitation on myocardial injury in patients with severe sepsis and septic shock].
    Zhang XL; Qin YJ; Bian XH; Dong SM
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2012 Apr; 24(4):222-4. PubMed ID: 22464575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study.
    Laterre PF; Garber G; Levy H; Wunderink R; Kinasewitz GT; Sollet JP; Maki DG; Bates B; Yan SC; Dhainaut JF;
    Crit Care Med; 2005 May; 33(5):952-61. PubMed ID: 15891319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Timing of drotrecogin alfa (activated) initiation in treatment of severe sepsis: a database cohort study of hospital mortality, length of stay, and costs.
    Ernst FR; Johnston JA; Pulgar S; He J; Ball DE; Young JK; Cooper LM
    Curr Med Res Opin; 2007 Jan; 23(1):235-44. PubMed ID: 17207305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation.
    Dhainaut JF; Yan SB; Joyce DE; Pettilä V; Basson B; Brandt JT; Sundin DP; Levi M
    J Thromb Haemost; 2004 Nov; 2(11):1924-33. PubMed ID: 15550023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of elevated cardiac troponin I in ESRD patients with sepsis.
    Kang EW; Na HJ; Hong SM; Shin SK; Kang SW; Choi KH; Lee HY; Han DS; Han SH
    Nephrol Dial Transplant; 2009 May; 24(5):1568-73. PubMed ID: 19145004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice.
    Ridley S; Lwin A; Wyncoll D; Lippett S; Watson D; Gunning K; Higgins D
    Eur J Anaesthesiol; 2008 Mar; 25(3):211-6. PubMed ID: 18031590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.